Folotyn FDA Approval History
FDA Approved: Yes (First approved September 24, 2009)
Brand name: Folotyn
Generic name: pralatrexate
Dosage form: Injection
Company: Allos Therapeutics, Inc.
Treatment for: Non-Hodgkin's Lymphoma
Folotyn (pralatrexate) is a folate analogue metabolic inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Development Timeline for Folotyn
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.